Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type
PMID
Authors
Title Talzenna (talazoparib) FDA Drug Label
URL https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651
Abstract Text

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Talazoparib Talazoparib 32 35
Drug Name Trade Name Synonyms Drug Classes Drug Description
Talazoparib Talzenna BMN673 PARP Inhibitor (Pan) 29 Talzenna (talazoparib) is an inhibitor of PARP1 and PARP2, which prevents the DNA repair of single strand DNA breaks, thus causing the accumulation of DNA strand breaks, genomic instability and apoptosis, and leads to lethality in homologous recombination repair deficient cells (PMID: 28242752). Talzenna (talazoparib) is FDA approved for use in patients with ERBB2 (HER2)-negative breast cancer harboring deleterious or suspected deleterious germline BRCA mutations, and in combination with Xtandi (enzalutamide) in patients with homologous recombination repair gene (ATM, ATR, BRCA1/2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C)-mutated metastatic castration-resistant prostate cancer (FDA.gov).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CHEK2 G151S prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including CHEK2 G151S (PMID: 42223064; NCT04821622). detail... detail... 42223064
ATM D2913Y prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM D2913Y (PMID: 42223064; NCT04821622). 42223064 detail... detail...
ATR inact mut prostate cancer sensitive Enzalutamide + Talazoparib FDA approved Actionable In a Phase III trial (TALAPRO-2) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median radiographic progression-free survival compared to enzalutamide plus placebo (27.9 vs 16.4 mo, HR 0.46, p=0.0003) in patients with metastatic castration-resistant prostate cancer harboring deficient homologous recombination repair genes including ATR, with an HR of 0.66 (p=0.12) in patients with non-BRCA mutations treated with Talzenna (talazoparib) (PMID: 37285865; NCT03395197). detail... 37285865
ATM R2227C prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM R2227C (PMID: 42223064; NCT04821622). detail... 42223064 detail...
ATM E2039K prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM E2039K (PMID: 42223064; NCT04821622). detail... 42223064 detail...
ATM inact mut prostate cancer sensitive Enzalutamide + Talazoparib FDA approved Actionable In a Phase III trial (TALAPRO-2) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median radiographic progression-free survival compared to enzalutamide plus placebo (27.9 vs 16.4 mo, HR 0.46, p=0.0003) in patients with metastatic castration-resistant prostate cancer harboring deficient homologous recombination repair genes including ATM, with an HR of 0.66 (p=0.12) in patients with non-BRCA mutations treated with Talzenna (talazoparib) (PMID: 37285865; NCT03395197). detail... 37285865
ATM D2625_A2626delinsEP prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM D2625_A2626delinsEP (PMID: 42223064; NCT04821622). 42223064 detail... detail...
ATM R2032K prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM R2032K (PMID: 42223064; NCT04821622). 42223064 detail... detail...
MLH1 inact mut prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including MLH1 rearrangement, copy number loss, nonsense, frameshift, or splice site variants (PMID: 42223064; NCT04821622). 42223064 detail... detail...
ATM A2067D prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM A2067D (PMID: 42223064; NCT04821622). 42223064 detail... detail...
CHEK2 inact mut prostate cancer sensitive Enzalutamide + Talazoparib FDA approved Actionable In a Phase III trial (TALAPRO-2) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median radiographic progression-free survival compared to enzalutamide plus placebo (27.9 vs 16.4 mo, HR 0.46, p=0.0003) in patients with metastatic castration-resistant prostate cancer harboring deficient homologous recombination repair genes including CHEK2, with an HR of 0.66 (p=0.12) in patients with non-BRCA mutations treated with Talzenna (talazoparib) (PMID: 37285865; NCT03395197). detail... 37285865
ATM D2708N prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM D2708N (PMID: 42223064; NCT04821622). 42223064 detail... detail...
ATM A2524P prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM A2524P (PMID: 42223064; NCT04821622). detail... detail... 42223064
ATM Y2470D prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM Y2470D (PMID: 42223064; NCT04821622). 42223064 detail... detail...
ATM inact mut prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM rearrangement, copy number loss, nonsense, frameshift, or splice site variants (PMID: 42223064; NCT04821622). detail... detail... 42223064
ATM R2832C prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM R2832C (PMID: 42223064; NCT04821622). 42223064 detail... detail...
ATM R2547_S2549del prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM R2547_S2549del (PMID: 42223064; NCT04821622). detail... 42223064 detail...
ATM F2827C prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM F2827C (PMID: 42223064; NCT04821622). detail... 42223064 detail...
CHEK2 R117G prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including CHEK2 R117G (PMID: 42223064; NCT04821622). 42223064 detail... detail...
CHEK2 inact mut prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including CHEK2 rearrangement, copy number loss, nonsense, frameshift, or splice site variants (PMID: 42223064; NCT04821622). 42223064 detail... detail...
ATM P292L prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM P292L (PMID: 42223064; NCT04821622). 42223064 detail... detail...
ATM V2662D prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM V2662D (PMID: 42223064; NCT04821622). detail... 42223064 detail...
ATM R3008H prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM R3008H (PMID: 42223064; NCT04821622). 42223064 detail... detail...
RAD51C inact mut prostate cancer sensitive Enzalutamide + Talazoparib FDA approved Actionable In a Phase III trial (TALAPRO-2) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median radiographic progression-free survival compared to enzalutamide plus placebo (27.9 vs 16.4 mo, HR 0.46, p=0.0003) in patients with metastatic castration-resistant prostate cancer harboring deficient homologous recombination repair genes including RAD51C, HR was 0.66 (p=0.12) in patients with non-BRCA mutations treated with Talzenna (talazoparib) (PMID: 37285865; NCT03395197). 37285865 detail...
RAD51C L219S prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including RAD51C L219S (PMID: 42223064; NCT04821622). detail... 42223064 detail...
MLH1 inact mut prostate cancer sensitive Enzalutamide + Talazoparib FDA approved Actionable In a Phase III trial (TALAPRO-2) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median radiographic progression-free survival compared to enzalutamide plus placebo (27.9 vs 16.4 mo, HR 0.46, p=0.0003) in patients with metastatic castration-resistant prostate cancer harboring deficient homologous recombination repair genes including MLH1, with an HR of 0.66 (p=0.12) in patients with non-BRCA mutations treated with Talzenna (talazoparib) (PMID: 37285865; NCT03395197). 37285865 detail...
CHEK2 K373E prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including CHEK2 K373E (PMID: 42223064; NCT04821622). detail... 42223064 detail...
ATM A2622V prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM A2622V (PMID: 42223064; NCT04821622). detail... 42223064 detail...
CHEK2 A392V prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including CHEK2 A392V (PMID: 42223064; NCT04821622). detail... 42223064 detail...
ATM V2716A prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM V2716A (PMID: 42223064; NCT04821622). detail... 42223064 detail...
ATM S2855_V2856delinsRI prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM S2855_V2856delinsRI (PMID: 42223064; NCT04821622). detail... 42223064 detail...
ATR inact mut prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATR rearrangement, copy number loss, nonsense, frameshift, or splice site variants (PMID: 42223064; NCT04821622). 42223064 detail... detail...
ATM R3008C prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM R3008C (PMID: 42223064; NCT04821622). detail... 42223064 detail...
ATM G2765S prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM G2765S (PMID: 42223064; NCT04821622). 42223064 detail... detail...
MLH1 R265C prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including MLH1 R265C (PMID: 42223064; NCT04821622). 42223064 detail... detail...
ATM D2016G prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM D2016G (PMID: 42223064; NCT04821622). detail... 42223064 detail...
RAD51C inact mut prostate cancer sensitive Enzalutamide + Talazoparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) and Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including RAD51C rearrangement, copy number loss, nonsense, frameshift, or splice site variants (PMID: 42223064; NCT04821622). 42223064 detail... detail...